BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Agentix Corp. AGTX
11 fiscal years on record · USD · FY2025 reported · SEC filings only
$-485,636
Growth
—
Revenue, FY2025 · full 11-year series below
Revenue $M
Net income $M
FY2022 · Revenue 0.0 · Net income -1.4
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2021 · Operating -211825.1% · Net -211825.1%
ROE
FY2016 · ROE -7630.3%
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | 0.0 | 0.0 | · | · | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | · | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | · | · | · | · | · | · | · | −0.0 |
| EPS, diluted $ | −0.01 | −0.01 | −0.01 | · | −0.04 | −6.45 | −3875.40 | −0.06 | −0.05 | −0.03 | −0.04 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | −7630.3 | −269.2 | −174.1 |
| Shares out B | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 48 reconciliationsAUDITED
Reconciled in 11 of 19 fiscal years. 47 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inNevada
Fiscal year endsMarch 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2014